• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

艰难梭菌感染的小鼠复发模型。

Mouse relapse model of Clostridium difficile infection.

机构信息

Tufts Cummings School of Veterinary Medicine, North Grafton, Massachusetts 01536, USA.

出版信息

Infect Immun. 2011 Jul;79(7):2856-64. doi: 10.1128/IAI.01336-10. Epub 2011 May 16.

DOI:10.1128/IAI.01336-10
PMID:21576341
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3191975/
Abstract

Clostridium difficile is the causative agent of primary and recurrent antibiotic-associated diarrhea and colitis in hospitalized patients. The disease is caused mainly by two exotoxins, TcdA and TcdB, produced by the bacteria. Recurrent C. difficile infection (CDI) constitutes one of the most significant clinical issues of this disease, occurs in more than 20% of patients after the first episode, and may be increasing in frequency. However, there is no well-established animal model of CDI relapse currently available for studying disease pathogenesis, prevention, and therapy. Here we report the establishment of a conventional mouse model of recurrence/relapse CDI. We found that the primary episode of CDI induced little or no protective antibody response against C. difficile toxins and mice continued shedding C. difficile spores. Antibiotic treatment of surviving mice induced a second episode of diarrhea, while a simultaneous reexposure of animals to C. difficile bacteria or spores elicited a full spectrum of CDI similar to that of the primary infection. Moreover, mice treated with immunosuppressive agents were prone to more severe and fulminant recurrent disease. Finally, utilizing this model, we demonstrated that vancomycin only delayed disease recurrence, whereas neutralizing polysera against both TcdA and TcdB completely protected mice against CDI relapse. In conclusion, we have established a mouse relapse CDI model that allows for future investigations of the role of the host immune response in the disease's pathogenesis and permits critical testing of new therapeutics targeting recurrent disease.

摘要

艰难梭菌是引起住院患者原发性和复发性抗生素相关性腹泻和结肠炎的病原体。该病主要由细菌产生的两种外毒素 TcdA 和 TcdB 引起。复发性艰难梭菌感染(CDI)是该病最主要的临床问题之一,在首次发作后超过 20%的患者中发生,且可能越来越频繁。然而,目前尚无用于研究疾病发病机制、预防和治疗的复发性 CDI 确立的动物模型。在这里,我们报告了复发性/迟发性 CDI 常规小鼠模型的建立。我们发现,CDI 的首次发作几乎不会引起针对艰难梭菌毒素的保护性抗体反应,并且小鼠持续排出艰难梭菌孢子。抗生素治疗存活的小鼠会引发第二次腹泻发作,而同时重新暴露于艰难梭菌细菌或孢子会引起与初次感染相似的全谱 CDI。此外,用免疫抑制剂治疗的小鼠更容易发生更严重和暴发性的复发性疾病。最后,利用该模型,我们证明了万古霉素仅延迟了疾病复发,而针对 TcdA 和 TcdB 的多克隆中和抗体则完全可以防止 CDI 复发。总之,我们建立了一种迟发性 CDI 小鼠模型,该模型可用于进一步研究宿主免疫反应在疾病发病机制中的作用,并可对针对复发性疾病的新疗法进行关键测试。

相似文献

1
Mouse relapse model of Clostridium difficile infection.艰难梭菌感染的小鼠复发模型。
Infect Immun. 2011 Jul;79(7):2856-64. doi: 10.1128/IAI.01336-10. Epub 2011 May 16.
2
Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections.确定艰难梭菌感染期间TcdA和TcdB在局部胃肠道疾病、全身器官损伤及宿主反应中的作用。
mBio. 2015 Jun 2;6(3):e00551. doi: 10.1128/mBio.00551-15.
3
A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.嵌合毒素疫苗可预防原发性和复发性艰难梭菌感染。
Infect Immun. 2012 Aug;80(8):2678-88. doi: 10.1128/IAI.00215-12. Epub 2012 May 21.
4
Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease.抗 TcdB 抗体,而非 TcdA 抗体,可预防胃肠道和全身艰难梭菌疾病的发生。
J Infect Dis. 2013 Jan 15;207(2):323-30. doi: 10.1093/infdis/jis669. Epub 2012 Nov 2.
5
A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice.一种新型多价、单域抗体靶向 TcdA 和 TcdB,可预防小鼠爆发性艰难梭菌感染。
J Infect Dis. 2014 Sep 15;210(6):964-72. doi: 10.1093/infdis/jiu196. Epub 2014 Mar 27.
6
Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.新型艰难梭菌抗毒素(TcdA和TcdB)人源化单克隆抗体在体外对多种临床菌株具有中和作用,并在仓鼠孢子攻击模型中展现出体内效力。
PLoS One. 2016 Jun 23;11(6):e0157970. doi: 10.1371/journal.pone.0157970. eCollection 2016.
7
Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.艰难梭菌感染重组毒素片段疫苗的研发
Vaccine. 2014 May 19;32(24):2812-8. doi: 10.1016/j.vaccine.2014.02.026. Epub 2014 Mar 21.
8
Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.单克隆抗毒素抗体actoxumab和bezlotoxumab预防艰难梭菌感染的机制。
Infect Immun. 2015 Feb;83(2):822-31. doi: 10.1128/IAI.02897-14. Epub 2014 Dec 8.
9
Genomic and Phenotypic Characterization of the Nontoxigenic Clostridioides difficile Strain CCUG37785 and Demonstration of Its Therapeutic Potential for the Prevention of C. difficile Infection.非产毒艰难梭菌 CCUG37785 株的基因组和表型特征及其预防艰难梭菌感染的治疗潜力的研究
Microbiol Spectr. 2022 Apr 27;10(2):e0178821. doi: 10.1128/spectrum.01788-21. Epub 2022 Mar 22.
10
Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure.经直肠滴注艰难梭菌毒素 A 可引发结肠炎症和组织损伤:艰难梭菌毒素暴露的新型且高效的小鼠模型的建立。
Infect Immun. 2012 Dec;80(12):4474-84. doi: 10.1128/IAI.00933-12. Epub 2012 Oct 8.

引用本文的文献

1
Preclinical evaluation of 6-Gingerol in modulating gut microbiota and SCFAs to mitigate -associated diarrhea in mice.6-姜酚调节肠道微生物群和短链脂肪酸以减轻小鼠相关腹泻的临床前评估。
Front Chem. 2025 Aug 28;13:1635781. doi: 10.3389/fchem.2025.1635781. eCollection 2025.
2
toxin A and toxin B inhibit toxin-specific adaptive immune responses through glucosyltransferase-dependent activity.毒素A和毒素B通过依赖葡萄糖基转移酶的活性抑制毒素特异性适应性免疫反应。
bioRxiv. 2025 Aug 2:2025.07.30.667646. doi: 10.1101/2025.07.30.667646.
3
Methods of a Reproducible Mouse Model of Clostridioides difficile Infection to Investigate Novel Bacterial-Based Therapies.用于研究新型基于细菌疗法的艰难梭菌感染可重复小鼠模型的方法
Methods Mol Biol. 2025;2942:103-116. doi: 10.1007/978-1-0716-4627-4_9.
4
's virulence requires efficient holin-mediated toxin secretion.其毒力需要通过有效的孔蛋白介导的毒素分泌来实现。
iScience. 2025 May 7;28(6):112586. doi: 10.1016/j.isci.2025.112586. eCollection 2025 Jun 20.
5
Control of virulence and physiology by the flagellin homeostasis checkpoint FliC-FliW-CsrA in the absence of motility.在缺乏运动性的情况下,通过鞭毛蛋白稳态检查点FliC-FliW-CsrA控制毒力和生理状态。
mBio. 2025 Mar 12;16(3):e0380124. doi: 10.1128/mbio.03801-24. Epub 2025 Jan 30.
6
Progranulin protects against infection by enhancing IL-22 production.颗粒蛋白前体通过增强 IL-22 的产生来抵抗 感染。
Gut Microbes. 2024 Jan-Dec;16(1):2409220. doi: 10.1080/19490976.2024.2409220. Epub 2024 Sep 30.
7
The state of play of rodent models for the study of infection.啮齿动物模型在 感染研究中的应用现状。
J Med Microbiol. 2024 Jul;73(7). doi: 10.1099/jmm.0.001857.
8
Deficiency of IL-22-binding protein enhances the ability of the gut microbiota to protect against enteric pathogens.白细胞介素-22 结合蛋白缺乏可增强肠道微生物群预防肠道病原体的能力。
Proc Natl Acad Sci U S A. 2024 May 7;121(19):e2321836121. doi: 10.1073/pnas.2321836121. Epub 2024 Apr 30.
9
Reviewing the Mouse Model: Insights into Infection Mechanisms.回顾小鼠模型:对感染机制的见解。
Microorganisms. 2024 Jan 27;12(2):273. doi: 10.3390/microorganisms12020273.
10
Probiotics for Prevention and Treatment of Clostridium difficile Infection.益生菌预防和治疗艰难梭菌感染。
Adv Exp Med Biol. 2024;1435:101-116. doi: 10.1007/978-3-031-42108-2_6.

本文引用的文献

1
Murine model of Clostridium difficile infection with aged gnotobiotic C57BL/6 mice and a BI/NAP1 strain.艰难梭菌感染的 aged gnotobiotic C57BL/6 小鼠和 BI/NAP1 株的鼠模型。
J Infect Dis. 2010 Dec 1;202(11):1708-12. doi: 10.1086/657086. Epub 2010 Oct 26.
2
Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid.利用胆酸类似物(如鹅去氧胆酸)抑制艰难梭菌孢子萌发的起始。
J Bacteriol. 2010 Oct;192(19):4983-90. doi: 10.1128/JB.00610-10. Epub 2010 Jul 30.
3
Piglet models of acute or chronic Clostridium difficile illness.急性或慢性艰难梭菌病的小猪模型。
J Infect Dis. 2010 Feb 1;201(3):428-34. doi: 10.1086/649799.
4
Antibiotic treatment of clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts.对艰难梭菌携带小鼠进行抗生素治疗会引发超级排菌状态、孢子介导的传播以及免疫功能低下宿主的严重疾病。
Infect Immun. 2009 Sep;77(9):3661-9. doi: 10.1128/IAI.00558-09. Epub 2009 Jun 29.
5
Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes.复发性艰难梭菌感染:危险因素、治疗方法及预后综述
J Infect. 2009 Jun;58(6):403-10. doi: 10.1016/j.jinf.2009.03.010. Epub 2009 Apr 5.
6
An ultrasensitive rapid immunocytotoxicity assay for detecting Clostridium difficile toxins.一种用于检测艰难梭菌毒素的超灵敏快速免疫细胞毒性测定法。
J Microbiol Methods. 2009 Jul;78(1):97-100. doi: 10.1016/j.mimet.2009.04.007. Epub 2009 Apr 23.
7
Recurrent Clostridium difficile infection: causality and therapeutic approaches.艰难梭菌反复感染:因果关系及治疗方法
Int J Antimicrob Agents. 2009 Mar;33 Suppl 1:S33-6. doi: 10.1016/S0924-8579(09)70014-7.
8
A mouse model of Clostridium difficile-associated disease.艰难梭菌相关性疾病的小鼠模型
Gastroenterology. 2008 Dec;135(6):1984-92. doi: 10.1053/j.gastro.2008.09.002. Epub 2008 Sep 10.
9
A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity.万古霉素与甲硝唑治疗艰难梭菌相关性腹泻的比较,按疾病严重程度分层
Clin Infect Dis. 2007 Aug 1;45(3):302-7. doi: 10.1086/519265. Epub 2007 Jun 19.
10
Update on Clostridium difficile associated disease.艰难梭菌相关疾病的最新情况
Curr Opin Gastroenterol. 2007 Jan;23(1):4-9. doi: 10.1097/MOG.0b013e32801184ac.